C4 Therapeutics Inc Ordinary Shares CCCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Insmed Appoints Two New Directors to Its Board
-
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
-
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
-
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
-
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $3.18
- Day Range
- $3.02–3.17
- 52-Week Range
- $1.69–5.17
- Bid/Ask
- $3.00 / $3.20
- Shares Outstanding
- 123.03M
- Market Cap
- $376.46M
- Volume/Avg
- 5M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 104
- Website
- https://www.c4therapeutics.com
Valuation
|
Metric
|
CCCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.52 |
Price/Sales | 9.72 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CCCC
|
|---|---|
Quick Ratio | 5.29 |
Current Ratio | 5.45 |
Interest Coverage | — |
Quick Ratio
CCCC
Profitability
|
Metric
|
CCCC
|
|---|---|
Return on Assets (Normalized) | −21.86% |
Return on Equity (Normalized) | −32.99% |
Return on Invested Capital (Normalized) | −29.58% |
Return on Assets
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|mKPvZ? | LOCK|@hS# | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|lk@ZM^$ | LOCK|X>Nf | $83B | |||
| Moderna Inc
MRNA
| LOCK|fylJ>% | LOCK|qn& | $80B | |||
| argenx SE ADR
ARGX
| LOCK|hs?k#n | LOCK|LK | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#rs@P@ | LOCK|WB& | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<Z%@?!Y | LOCK|!RFJ% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&k@#zQ! | LOCK|@?LT | $28B | |||
| Incyte Corp
INCY
| LOCK|vWKZ#$ | LOCK|xWq | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>J^%Kx | LOCK|#g | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#M?^$q | LOCK|<j | $14B |
United States